A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Kelly, William Kevin
Hussain, Arif
Saraiya, Biren
Thanigaimani, Pradeep
Sun, Furong
Seebach, Frank A.
Lowy, Israel
Sandigursky, Sabina
Miller, Elizabeth
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA USA
[2] Univ Maryland, Med Ctr, Baltimore, MD USA
[3] Rutgers State Univ, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA
[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS284
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
    Choudhury, Atish Dipankar
    Xie, Wanling
    Folefac, Edmund
    Lee, Daniel
    Parikh, Mamta
    Einstein, David Johnson
    Kessler, Elizabeth R.
    Mayer, Tina M.
    McKay, Rana R.
    Pace, Amanda Fredericks
    Kochupurakkal, Bose
    Mouw, Kent William
    Van Allen, Eliezer Mendel
    Kunos, Charles
    D'Andrea, Alan D.
    Taplin, Mary-Ellen
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
    Vander Weele, David James
    Kocherginsky, Masha
    Munir, Sabah
    Martone, Brenda K.
    Morgans, Alicia K.
    Stadler, Walter Michael
    Abdulkadir, Sarki
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
    Morris, Michael J.
    Rathkopf, Dana E.
    Novotny, William
    Gibbons, Jacqueline A.
    Peterson, Amy C.
    Khondker, Zakaria
    Ouatas, Taoufik
    Scher, Howard I.
    Fleming, Mark T.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3774 - 3781
  • [24] Phase 1 efficacy and pharmacodynamic results of exicorilant plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Morris, Michael J.
    Linch, Mark David
    Crabb, Simon J.
    Beer, Tomasz M.
    Heath, Elisabeth I.
    Gordon, Michael S.
    De Bono, Johann S.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Greenstein, Andrew E.
    Mann, Grace
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [25] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
    Choudhury, Atish Dipankar
    Xie, Wanling
    Parikh, Mamta
    Lee, Daniel
    Kessler, Elizabeth R.
    Einstein, David Johnson
    Kochupurakkal, Bose
    Mouw, Kent William
    Van Allen, Eliezer Mendel
    Doyle, L. Austin
    D'Andrea, Alan D.
    Taplin, Mary-Ellen
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer
    Hackenbruch, Christopher
    Heitmann, Jonas S.
    Walz, Juliane S.
    Federmann, Birgit
    Pfluegler, Martin
    Hadaschik, Boris A.
    Jung, Gundram
    Salih, Helmut R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
    Lim, Emerson A.
    Schweizer, Michael T.
    Chi, Kim N.
    Aggarwal, Rahul
    Agarwal, Neeraj
    Gulley, James
    Attiyeh, Edward
    Greger, James
    Wu, Shujian
    Jaiprasart, Pharavee
    Loffredo, John
    Bandyopadhyay, Nibedita
    Xie, Hong
    Hansen, Aaron R.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 366 - 375
  • [30] A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
    Bryce, Alan Haruo
    Karp, Daniel D.
    Tagawa, Scott T.
    Nordquist, Luke T.
    Rathkopf, Dana E.
    Adra, Nabil
    Dorff, Tanya B.
    Baeck, Johan
    O'Donnell, Joseph Francis
    Ames, Tyler David
    Yim, Christina Y.
    Price, Matthew
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345